Brochure Available for the World Vaccine Congress

1 Event, 7 Conferences at the World Vaccine Congress 2015 The World Vaccine Congress is back for it’s 15th year on April 7-9 in Washington. With over 250 people already signed up to attend, ranging from pharma and biotech, to non-profits and governmental departments, it is set to be another great year. The event has grown for 2015. Not only …

vaccine manufacturers

Top 3 Sparks of Interest for Leading Vaccine Academics

Recently we undertook the research for the 15th annual World Vaccine Congress. As part of that research, we spoke to leading vaccine academics from the likes of University of Oxford and Erasmus MC to find out what they thought were the most interesting trends in industry at the moment. These were the top 3: 1. The renaissance of veterinary vaccines …

Vaccine Asia Live: Recombinant Lipoimmunogen-based therapeutic HPV Vaccine

Human Papilloma Virus(HPV) is a DNA virus that can cause skin & genital warts as well as cervical and osopharyngeal cancers. In the US, there is an increasing trend in cervical cancer in women and osopharyngeal cancer in men.  To make things worse, there are no treatments available for HPV infection. Thus, HPV vaccines have become the most common mode …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

GSK Cancer Vaccine Fails to Meet Phase III Primary Endpoints Again

Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population March 20, 2014 GlaxoSmithKline plc (GSK) today announced that analysis of the MAGRIT trial, a phase …

MD Anderson, MedImmune Join Forces to Advance Cancer Immunotherapy

March 13, 2014 The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson’s Moon Shots Program to develop therapies that unleash patients’ immune systems to attack their cancers. “Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to …

Novartis expands cancer immunotherapy research program with acquisition of CoStim

February 17, 2014 Acquisition adds novel immune modulating targets and technology to accelerate Novartis cancer immunotherapy program Novartis and University of Pennsylvania CAR immunotherapy research combined with CoStim targets and technology strengthens Novartis’ position in cancer immunotherapy discovery Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, …

Therapeutic Cancer Vaccines: The failures

Cancer immunotherapy and cancer vaccines were named Science Magazine’s ‘Breakthrough of the Year 2013‘, but whilst the industry continues to be optimistic about the promises of harnessing a patients immune system to treat cancer, it’s hard to ignore the big disappointments that have been recorded in a number of high profile Phase III and II trial failures. Here are just …

Aquisition Boosts Medigene’s Immuno-oncology Portfolio

Frankfurt based Medigene last week acquired fellow Germans Trianta for the sum of €9.9 ($13.5). Trianta Immnotherapies, a Munich based  start-up, develops novel cancer vaccines and development platforms, sepcialising in personalised T cell immunotherapy. The move will see Medigene gaining 15 of the country’s top cancer vaccine researchers from the German Research Center for Environmental Health (Helmholtz Zentrum Munchen). Trianta …

Experimental brain tumour vaccine gets straight to the source

The Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery have announced a phase 1 safety study testing the safety of a vaccine designed to target cancer stem cells in glioblastoma multiforme -the most common form of brain tumor in adults- in a bid to stop re-occurrence. Traditional chemotherapy and radiation treatments can only attack the cancer cells, which leaves …